200 related articles for article (PubMed ID: 23280503)
1. AKT inhibition mitigates GRP78 (glucose-regulated protein) expression and contribution to chemoresistance in endometrial cancers.
Gray MJ; Mhawech-Fauceglia P; Yoo E; Yang W; Wu E; Lee AS; Lin YG
Int J Cancer; 2013 Jul; 133(1):21-30. PubMed ID: 23280503
[TBL] [Abstract][Full Text] [Related]
2. Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma.
Xia YZ; Yang L; Xue GM; Zhang C; Guo C; Yang YW; Li SS; Zhang LY; Guo QL; Kong LY
Oncotarget; 2016 Aug; 7(35):56371-56382. PubMed ID: 27486760
[TBL] [Abstract][Full Text] [Related]
3. Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Gifford JB; Huang W; Zeleniak AE; Hindoyan A; Wu H; Donahue TR; Hill R
Mol Cancer Ther; 2016 May; 15(5):1043-52. PubMed ID: 26939701
[TBL] [Abstract][Full Text] [Related]
4. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.
Duan L; Perez RE; Hansen M; Gitelis S; Maki CG
Cancer Biol Ther; 2014; 15(12):1600-12. PubMed ID: 25482935
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.
Pant A; Lee II; Lu Z; Rueda BR; Schink J; Kim JJ
PLoS One; 2012; 7(7):e41593. PubMed ID: 22911820
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen-induced cytotoxicity in breast cancer cells is mediated by glucose-regulated protein 78 (GRP78) via AKT (Thr308) regulation.
Pujari R; Jose J; Bhavnani V; Kumar N; Shastry P; Pal JK
Int J Biochem Cell Biol; 2016 Aug; 77(Pt A):57-67. PubMed ID: 27262235
[TBL] [Abstract][Full Text] [Related]
7. GRP78 induced by estrogen plays a role in the chemosensitivity of endometrial cancer.
Luvsandagva B; Nakamura K; Kitahara Y; Aoki H; Murata T; Ikeda S; Minegishi T
Gynecol Oncol; 2012 Jul; 126(1):132-9. PubMed ID: 22543280
[TBL] [Abstract][Full Text] [Related]
8. Akt is the downstream target of GRP78 in mediating cisplatin resistance in ER stress-tolerant human lung cancer cells.
Lin Y; Wang Z; Liu L; Chen L
Lung Cancer; 2011 Mar; 71(3):291-7. PubMed ID: 20599289
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of GRP78 enhances cell death by cisplatin and radiotherapy in nasopharyngeal cells.
Huang YY; Pu LJ; Song LL; Ma LY; Liu H; Jiang CC
Anticancer Drugs; 2016 Sep; 27(8):726-33. PubMed ID: 27254284
[TBL] [Abstract][Full Text] [Related]
10. Involvement of Akt isoforms in chemoresistance of endometrial carcinoma cells.
Girouard J; Lafleur MJ; Parent S; Leblanc V; Asselin E
Gynecol Oncol; 2013 Feb; 128(2):335-43. PubMed ID: 23174537
[TBL] [Abstract][Full Text] [Related]
11. The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin.
Chon HS; Marchion DC; Xiong Y; Chen N; Bicaku E; Stickles XB; Bou Zgheib N; Judson PL; Hakam A; Gonzalez-Bosquet J; Wenham RM; Apte SM; Lancaster JM
Gynecol Oncol; 2012 Jan; 124(1):119-24. PubMed ID: 22032837
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer.
Kashyap T; Pramanik KK; Nath N; Mishra P; Singh AK; Nagini S; Rana A; Mishra R
Oral Oncol; 2018 Nov; 86():234-243. PubMed ID: 30409306
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
You KS; Yi YW; Kwak SJ; Seong YS
Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
[TBL] [Abstract][Full Text] [Related]
14. Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells.
Jiang CC; Mao ZG; Avery-Kiejda KA; Wade M; Hersey P; Zhang XD
Carcinogenesis; 2009 Feb; 30(2):197-204. PubMed ID: 18842681
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of HOXA11 enhances endometrial cancer malignancy and cisplatin resistance via activating PTEN/AKT signaling pathway.
Kong C; Zhu Z; Li Y; Xue P; Chen L
Clin Transl Oncol; 2021 Jul; 23(7):1334-1341. PubMed ID: 33515421
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin increases B-cell-lymphoma-2 expression via activation of protein kinase C and Akt2 in endometrial cancer cells.
Rouette A; Parent S; Girouard J; Leblanc V; Asselin E
Int J Cancer; 2012 Apr; 130(8):1755-67. PubMed ID: 21618512
[TBL] [Abstract][Full Text] [Related]
17. Association between the unfolded protein response, induced by 2-deoxyglucose, and hypersensitivity to cisplatin: a mechanistic study employing molecular genomics.
Gaddameedhi S; Chatterjee S
J Cancer Res Ther; 2009 Sep; 5 Suppl 1():S61-6. PubMed ID: 20009298
[TBL] [Abstract][Full Text] [Related]
18. [Small interfering RNA-mediated glucose-regulated protein 78 knockdown enhances chemosensitivity of breast cancer cells to cisplatin].
Pu L; Huang Y; Li Y; Xu J; Jiang C; Liu H; Jiang Z
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jan; 33(1):44-7. PubMed ID: 23353154
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer.
Stottrup C; Tsang T; Chin YR
Mol Cancer Ther; 2016 Aug; 15(8):1964-74. PubMed ID: 27297869
[TBL] [Abstract][Full Text] [Related]
20. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
